Partnering opportunities we are looking for:

  • Retinal diseases (including AMD, DME, RVO, DR)

  • Glaucoma

  • Dry eye disease

  • Vision restoration through gene therapy and cell-based therapy approaches

Example partnerships

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.

We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes novel therapeutic modalities such as gene therapies, cell-based therapies and potential treatments for geographic atrophy (GA).

Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to preserve and restore vision.

Your dedicated partnering leads in Ophthalmology

Tom Zioncheck
Head of Neuroscience, Ophthalmology and Rare Diseases, Pharma Partnering
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

Contact our Pharma Partnering Team

Interested in partnering with us?

More Pharma partnering areas

View all areas


  1. Word Health Organization. Blindness and vision impairment. [Internet; cited April 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment

Discover more